The adoption of Syapse Precision Medicine Platform will help deliver large-scale genomic and clinical data to enhance patient care
SEATTLE, April 23, 2015 – The Swedish Cancer Institute (SCI), one of the Northwest’s leading cancer treatment centers, announced today the adoption of Syapse Precision Medicine Platform to enhance its Personalized Medicine Program. The innovative software platform will enable clinicians to better integrate genomic information into patient care and move critical cancer research forward.
The Personalized Medicine Program, launched in April 2014, combines advanced treatments based on the “molecular fingerprint” of a tumor with individualized emotional and physical supportive care. SCI’s gene alteration panel, developed in partnership with CellNetix Pathology & Laboratories, is based on a focused set of gene alterations that are most relevant to cancer treatments. By combining gene alteration data with the clinical decision support of the Syapse platform, patients may receive tailored therapies or targeted clinical trials specific to their molecular fingerprint instead of treatments based solely on the origin of their cancer.